LivaNova PLC (LIVN)

NASDAQ • Healthcare

$81.27

+$2.82 (+3.6%)

Market closed

Last close at October 22, 2026 at 20:00 UTC

Open$78.7

Day Range$78.35 - $81.42

Avg. Volume (3M)621.8K

Market Cap$4.3B

P/E Ratio23.6

52 Week Range

$48.82$85.76

Next EarningsIn 13 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$390.6M100%

Gross Profitminus cost of goods$273.7M70%

Operating Incomeminus R&D and overhead$49.5M13%

Net Incomeminus taxes and the rest$108.6M28%

In plain terms: out of every $100 in revenue, LivaNova PLC keeps $28 as net profit.

Fundamentals & Financials

Revenue (TTM)

$1.4B

Net Income (TTM)

$188.5M

EPS (TTM)

$3.45

ROA (TTM)

7.14%

Current Ratio

1.45

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+25.0%Q3 2025$1.05

+20.8%Q4 2025$1.11

+7.5%Q1 2026$0.86

+15.3%Q2 2026$0.98

+15.6%Q3 2026$1.26

Nov 4

in 13 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +15.6%

LivaNova topped expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 5, 2026, as revenue of $390.6 million topped the $380.5 million estimate (+2.7%, verdict: topped) and adjusted EPS of $1.26 topped the $1.09 estimate (+15.6%, verdict: topped). Revenue rose 10.8% to about $390.6 million from roughly $352.5 million a year ago, reflecting results across its cardiopulmonary care, neuromodulation, and temporary life support device businesses. Profitability stayed elevated, with gross margin near 70% and operating margin around 13%, alongside operating income of about $49.5 million. The company generated operating cash flow of roughly $66.6 million in the quarter. For the next period, consensus calls for EPS of $1.04 on revenue of $381.1 million.

Next report — what to expect

LivaNova PLC (LIVN) reports on November 4, 2026, with consensus calling for EPS of $1.06 on revenue of $381.1 million. For trailing context, revenue grew +10.8% year over year last quarter. The company has beaten EPS in 8 of 8 most recent quarters, making upside vs. estimates a key watchpoint.

View full earnings history

About LivaNova PLC

LivaNova PLC designs and sells medical technology for cardiopulmonary care, neuromodulation, and temporary life support, with $1.4 billion in FY2025 revenue. Listed on NASDAQ as LIVN, the company operates in the healthcare sector through device businesses used in heart-lung procedures, vagus nerve stimulation, and acute circulatory or respiratory support.

Name

LivaNova PLC

CEO

Vladimir A. Makatsaria

Website

www.livanova.com

Industry

Healthcare

Year Founded

1987

Employees

3,300

Today's Snapshot

AI-generated

The day ended with LIVN 3.6% higher at 81.27, in line with a firmer sector. LIVN reports earnings on 4 November.

Trading Volume

Below 10d avg (594.5K)

511K

vs S&P 500 Today

Strong Outperformance

+4.87%

Updated: October 22, 2026 at 20:10 UTC

Technical Indicators

6 Buy1 Neutral1 Sell

LIVN presents a bullish technical stance with price trading above its short- and long-term moving averages and above the pivot near 79.23, supported by strong momentum readings—notably a high CCI and a positive MACD. RSI is healthy without being overbought, and OBV shows positive accumulation, while ADX indicates a non-dominant but present trend. Volatility is moderate with ATR in low-single-digit dollars, implying orderly movement. Overall indicators coalesce toward an upward bias. Technical takeaway: Buy.

All signals